Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Erlotinib +/- Radiation for Resectable Pancreatic Cancer
NCT00766636Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2008
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2008; status: terminated.
02
Drugs
erlotinibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00766636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00766636.